UCB (Euronext Brussels: UCB) announced that the U.S. Food and Drug Administration approved KYGEVVI (doxecitine and doxribtimine) for treating thymidine ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE